2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis
Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …
Clinical, laboratory, radiographic, and histopathologic features of methotrexate‐associated lung injury in patients with rheumatoid arthritis. A multicenter study with …
JM Kremer, GS Alarcón, ME Weinblatt… - Arthritis & …, 1997 - Wiley Online Library
Objective. To describe the clinical, laboratory, radiologic, and histopathologic features of
methotrexate (MTX)‐induced lung injury in a combined cohort of selected patients with …
methotrexate (MTX)‐induced lung injury in a combined cohort of selected patients with …
B‐lymphocyte contributions to human autoimmune disease
K Yanaba, JD Bouaziz, T Matsushita… - Immunological …, 2008 - Wiley Online Library
Autoimmunity results from abnormal B‐and T‐cell recognition of self‐antigens, which leads
to autoantibody production in many cases. Autoantibodies produced by B‐cell‐derived …
to autoantibody production in many cases. Autoantibodies produced by B‐cell‐derived …
[HTML][HTML] Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky, DMFM van der Heijde… - … England Journal of …, 2000 - Mass Medical Soc
Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …
[HTML][HTML] Rituximab versus cyclophosphamide for ANCA-associated vasculitis
JH Stone, PA Merkel, R Spiera, P Seo… - … England Journal of …, 2010 - Mass Medical Soc
Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA) …
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA) …
2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis
L Fraenkel, JM Bathon, BR England… - Arthritis & …, 2021 - Wiley Online Library
Objective To develop updated guidelines for the pharmacologic management of rheumatoid
arthritis. Methods We developed clinically relevant population, intervention, comparator, and …
arthritis. Methods We developed clinically relevant population, intervention, comparator, and …
[PDF][PDF] 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data …
CH Shiboski, SC Shiboski, R Seror… - Arthritis & …, 2017 - Wiley Online Library
Objective To develop and validate an international set of classification criteria for primary
Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology …
Sjögren's syndrome (SS) using guidelines from the American College of Rheumatology …
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a …
R Maini, EW St Clair, F Breedveld, D Furst, J Kalden… - The Lancet, 1999 - thelancet.com
Background Not all patients with rheumatoid arthritis can tolerate or respond to
methotrexate, a standard treatment for this disease. There is evidence that antitumour …
methotrexate, a standard treatment for this disease. There is evidence that antitumour …
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
EW St. Clair, DMFM Van Der Heijde… - Arthritis & …, 2004 - Wiley Online Library
Objective. To compare the benefits of initiating treatment with methotrexate (MTX) and
infliximab (anti–tumor necrosis factor [anti-TNF] monoclonal antibody) with those of MTX …
infliximab (anti–tumor necrosis factor [anti-TNF] monoclonal antibody) with those of MTX …
Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells
Y Iwata, T Matsushita, M Horikawa… - Blood, The Journal …, 2011 - ashpublications.org
Regulatory B cells control inflammation and autoimmunity in mice, including the recently
identified IL-10–competent B10 cell subset that represents 1% to 3% of spleen B cells. In this …
identified IL-10–competent B10 cell subset that represents 1% to 3% of spleen B cells. In this …